Simmons Jeffrey N 4

What Happened
Jeffrey N. Simmons, President, CEO and Director of Elanco Animal Health Inc., was granted 4,497.619 deferred stock units on March 6, 2026. The units were valued at $23.36 each for a total grant value of about $105,064. This was an award/derivative grant (Form 4 code A), not an open‑market purchase or sale.

Key Details

• Transaction date: 2026-03-06; Filing date (Form 4): 2026-03-10 (appears late—Form 4s are typically due within 2 business days).
• Grant details: 4,497.619 deferred stock units at $23.36 per unit; total ≈ $105,064.
• Shares owned after transaction: not reported in this filing.
• Footnotes:
  • F1 — Each deferred stock unit represents the right to receive one share of common stock or the cash equivalent.
  • F2 — Units settle in cash or shares following termination of employment or in a specified future year under the Executive Deferral and Stock Match Plan.
• Transaction type: Award of deferred/derivative units (code A).

Context
This was a compensation award (deferred stock units) rather than a purchase or sale; such grants are part of executive pay and may vest or settle later in cash or shares per the company plan. Because it’s an award, it shouldn’t be read as a direct market purchase signal. The delayed filing may be notable to compliance‑minded investors but does not change the economic nature of the grant.